Duggan Robert W's Form 4 filing
Pulse Biosciences, Inc. (PLSE) · filed Dec 8, 2023
- Accession no.
- 0001437749-23-034041
- Filed
- Dec 8, 2023
- Trade date
- Dec 6, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market purchases total $750.3K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Duggan Robert WCIK 0001055919 | Director, 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 6, 2023 | Common Stock | MOption exerciseAcquired | +9,933 | $5.95 | +$59,101.35 | 36,601,741 | Direct | |
| Dec 6, 2023 | Common Stock | PPurchaseAcquired | +82,813 | $9.06 | +$750,285.78 | 36,684,554 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 6, 2023 | Common Stock | MOption exerciseDisposed | −9,933 | $0.00 | $0 | 0 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.